Oramed Pharmaceuticals (ORMP)

Common Shares

Sell: $2.19|Buy: $2.26|Change: 0.04 (-1.76%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

$2.21

Previous close

$2.27

Trade high

$2.27

Volume

60,833

Year high

$3.09

Year low

$1.82

Dividend yield

–

Market capitalisation

$91.44 mn

P/E ratio

20.91

ISIN

US68403P2039

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 17/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Oramed Pharmaceuticals	- 1.76
More...

Company profile

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.